연구성과로 돌아가기

2023 연구자 정보 (47 / 1135)

※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Author Name 제1저자 여부 ⓘ 교신저자 여부 ⓘ Address ResearcherID ORCID Paper Title WoS Edition 최상위 JCR(%) WoS Category Related Email
Han, Jae Joon
(Han, JJ) ⓘ 		Kyung Hee Univ, Med Ctr, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] The Co-Occurrence of bZIP in-Frame CEBPA-Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia ⓘ SCIE ⓘ 1.5 HEMATOLOGY ⓘ ⓘ
Hong Duc Nguyen Thi
(Thi, HDN) ⓘ 		Kyungpook Natl Univ, Grad Sch, Dept Biomed Sci, Daegu, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Combinatorial Optimization of Chemotherapeutic Agents on T-Cell Acute Lymphoblastic Leukemia ⓘ SCIE ⓘ 1.5 HEMATOLOGY ⓘ ⓘ
Hu, Jia
(Hu, J) ⓘ 		Aptose Biosci, San Diego, CA USA ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) ⓘ SCIE ⓘ 1.5 HEMATOLOGY ⓘ ⓘ
Huh, So-Young
(Huh, SY) ⓘ 		Kosin Univ, Dept Neurol, Coll Med, Pusan, South Korea
Kosin Univ, Coll Med, Dept Neurol, Busan, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum
[JCR상위 13.4] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum ⓘ 		SCIE ⓘ 1.5 CLINICAL NEUROLOGY;PSYCHIATRY;SURGERY
CLINICAL NEUROLOGY;NEUROSCIENCES ⓘ 		bjkim@skku.edu;sueh916@gmail.com; ⓘ
Hwang, Sung-Chul
(Hwang, SC) ⓘ 		GET SCR Co Ltd, R&D Ctr, Mryang 50404, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Experimental and numerical investigation on a solar-driven torrefaction reactor using woody waste (Ashe Juniper) ⓘ SCIE ⓘ 1.5 ENERGY & FUELS;MECHANICS;THERMODYNAMICS ⓘ namhs219@knu.ac.kr; ⓘ
Jang, Hee Ryeong
(Jang, HR) ⓘ 		Kangwon Natl Univ Hosp, Chunchon, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study) ⓘ SCIE ⓘ 1.5 HEMATOLOGY ⓘ ⓘ
Jang, Jun Ho
(Jang, JH) ⓘ 		Samsung Med Ctr, Dept Internal Med, Div Hematol Oncol, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] The Co-Occurrence of bZIP in-Frame CEBPA-Mutation with Unfavorable Genetic Abnormalities Is Associated with a Poor Prognosis in Acute Myeloid Leukemia ⓘ SCIE ⓘ 1.5 HEMATOLOGY ⓘ ⓘ
Jang, Myoung-jin
(Jang, MJ) ⓘ 		Seoul Natl Univ Hosp, Med Res Collaborating Ctr, Seoul, South Korea
Seoul Natl Univ Hosp, Med Res Collaborat Ctr, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum
[JCR상위 13.4] Early rituximab treatment reduces long-term disability in aquaporin-4 antibody-positive neuromyelitis optica spectrum
[JCR상위 8.7] Personalized Antiviral Drug Selection in Patients With Chronic Hepatitis B Using a Machine Learning Model: A Multinational Study ⓘ 		SCIE ⓘ 1.5 CLINICAL NEUROLOGY;PSYCHIATRY;SURGERY
CLINICAL NEUROLOGY;NEUROSCIENCES
GASTROENTEROLOGY & HEPATOLOGY ⓘ 		bjkim@skku.edu;sueh916@gmail.com;
mhhur@snu.ac.kr;alsrud627@snu.ac.kr;terryfungyip@gmail.com;e580306@ms31.hinet.net;vital@snu.ac.kr;dr.choi85@gmail.com;KSUKOREA@yuhs.ac;limys@amc.seoul.kr;psyoung0419@gmail.com;wonglaihung@mect.cuhk.edu.hk;sinndhn@gmail.com;jyj412@hanmail.net;sekim@hallym.or.kr;cypeng@mail.cmuh.org.tw;drshp@khu.ac.kr;5137ccy@gmail.com;hwiyoung@gmail.com;amelia86@naver.com;gandorie@gmail.com;noshin@hanyang.ac.kr;mseileen80@hanyang.ac.kr;sonjh@hanyang.ac.kr;dr486@eulji.ac.kr;jshim3927@gmail.com;jeongsw@schmc.ac.kr;choyk2004.cho@samsung.com;hskim@kdh.or.kr;mjjang2014@naver.com;yoonjun@snu.ac.kr;yoonjh@snu.ac.kr;pindra@empal.com; ⓘ
Jeong, W. G.
(Jeong, WG) ⓘ 		Chonnam Natl Univ, Sch Med, Jeonnam, South Korea
Hwasun Hosp, Jeonnam, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy ⓘ SCIE ⓘ 1.5 ONCOLOGY;RESPIRATORY SYSTEM ⓘ ⓘ
Jeong, Won Gi
(Jeong, WG) ⓘ 		Hwasun Hosp, 322 Seoyang Ro, Hwasun 58128, Jeonnam, South Korea
Chonnam Natl Univ, Med Sch, Dept Radiol, Hwasun, Jeonnam, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR ⓘ SCIE ⓘ 1.5 ONCOLOGY;RESPIRATORY SYSTEM ⓘ droij@jnu.ac.kr; ⓘ
Ji, W.
(Ji, W) ⓘ 		Univ Ulsan, Coll Med, Asan Med Cenc, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Korean Real-world Data on Unresectable Stage III Non-Small Cell Lung Cancer Patients Treated with Durvalumab after Chemoradiotherapy ⓘ SCIE ⓘ 1.5 ONCOLOGY;RESPIRATORY SYSTEM ⓘ ⓘ
Ji, Wonjun
(Ji, WJ) ⓘ 		Univ Ulsan, Asan Med Ctr, Dept Pulm & Crit Care Med, Coll Med, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Korean Real-World Data on Patients With Unresectable Stage III NSCLC Treated With Durvalumab After Chemoradiotherapy: PACIFIC-KR ⓘ SCIE ⓘ 1.5 ONCOLOGY;RESPIRATORY SYSTEM ⓘ droij@jnu.ac.kr; ⓘ
Jonas, Brian A.
(Jonas, BA) ⓘ 		Univ Calif Davis, Div Malignant Hematol Cellular Therapy & Transpla, Dept Internal Med, Sch Med, Sacramento, CA USA ⓘ AAS-3639-2020
Jonas, Brian ⓘ
ⓘ 		[JCR상위 1.5] Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) ⓘ SCIE ⓘ 1.5 HEMATOLOGY ⓘ ⓘ
Jung, Chul W.
(Jung, CW) ⓘ 		Samsung Med Ctr, Seoul, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Tuspetinib Myeloid Kinase Inhibitor Safety and Efficacy As Monotherapy and Combined with Venetoclax in Phase 1/2 Trial of Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) ⓘ SCIE ⓘ 1.5 HEMATOLOGY ⓘ ⓘ
Jung, Jong Heon
(Jung, JH) ⓘ 		Natl Canc Ctr, Goyang, South Korea ⓘ
ⓘ
ⓘ 		[JCR상위 1.5] Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study) ⓘ SCIE ⓘ 1.5 HEMATOLOGY ⓘ ⓘ
페이지 이동: